


ML240

| | | | |
|--------------------|--|-------|----------|
| Cat. No.: | HY-19795 | | |
| CAS No.: | 1346527-98-7 | | |
| Molecular Formula: | C ₂₃ H ₂₀ N ₆ O | | |
| Molecular Weight: | 396.44 | | |
| Target: | p97 | | |
| Pathway: | Cell Cycle/DNA Damage | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 16.5 mg/mL (41.62 mM; Need ultrasonic and warming)

| Preparing Stock Solutions | Solvent | Mass | 1 mg | 5 mg | 10 mg |
|---------------------------|---------------|------|-----------|------------|------------|
| | Concentration | | | | |
| | 1 mM | | 2.5224 mL | 12.6122 mL | 25.2245 mL |
| | 5 mM | | 0.5045 mL | 2.5224 mL | 5.0449 mL |
| | 10 mM | | 0.2522 mL | 1.2612 mL | 2.5224 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ML240 is a potent p97 inhibitor, inhibiting p97 ATPase with IC₅₀ value of 100 nM.

IC₅₀ & Target

IC₅₀: 100 nM (p97)^[1]

In Vitro

ML240 is a potent p97 inhibitor, with an IC₅₀ of 100 nM. ML240 is active in the UbG76V-GFP stabilization assay (IC₅₀, 0.9 μM). ML240 inhibits p97 competitively with respect to ATP with a K_i values of 0.22 μM. ML240 also inhibits labeling of only three protein kinase domains by >50% when tested at 20 μM: PIP5 K3 (belongs to phosphoinositide-3 kinase family), JAK1 JH2 (N-terminal pseudokinase domain of JAK1), and DNAPK (DNA-dependent protein kinase). ML240 (1.1, 3.3, 10, or 20 μM) induces executioner caspases 3 and 7 and triggers cell death independently of apical caspases 8 and 9^[1]. ML240 is cytotoxic to HCT15 and SW403 cells, with GI₅₀s of 0.76 and 0.5 μM after treatment for 24 h, and 0.54 and 0.5 μM after treatment for 72 h, respectively^[2].

PROTOCOL

Cell Assay ^[2]

HeLa cells stably expressing ODD-luciferase are seeded onto a 96-well white solid bottom plate (**5000 cells/well**) and cells are grown for 16 h. Cells are treated with DMEM containing MG132 (4 μ M) for 1h and washed with 100 μ L PBS twice. DMEM containing 2.5% FBS, cycloheximide (50 μ g/mL) and **ML240** are added into the well. Four 96-well plates are prepared and one of the plates is taken out from incubator at each time point (70, 90, 120, or 150 min). Luciferin (50 μ L of 1 mg/mL in PBS) is added into each well containing 50 μ L of medium and incubated at room temperature with shaking at 500 rpm for 5 min. Luminescence intensity is determined with 0.1 ms integration time on the Synergy HT Microplate Reader^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chou TF et al. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem, 2013 Feb, 8(2):297-312.

[2]. Chou TF, et al. Selective, reversible inhibitors of the AAA ATPase p97. Probe Reports from the NIH Molecular Libraries Program. April 14, 2011.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA